Company profile BCDA

BioCardia Inc.
we are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. biocardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its cardiamp™ and cardiallo™ therapies. clinical results supporting both therapeutic programs are compelling and build upon the... most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. these programs are enabled by the company's helix™ transendocardial delivery systems and morph® vascular access products, which are partnered to enable other promising biotherapeutic programs. Show More
Quarter analysis & expected interestLast update: November 04 2023 01:04:29.

After 34 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 58 days it will total up to 0.0.
BioCardia expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).

YearQ1Q2Q3Q4
2018 - - - 0
2019 0
0
0
0
2020 0
0
36
inf% YoY inf% QoQ
208
inf% YoY 477.8% QoQ
2021 110
inf% YoY -47.1% QoQ
90
inf% YoY -18.2% QoQ
20
-44.4% YoY -77.8% QoQ
101
-51.4% YoY 405.0% QoQ
2022 84
-23.6% YoY -16.8% QoQ
111
23.3% YoY 32.1% QoQ
89
345.0% YoY -19.8% QoQ
32
-68.3% YoY -64.0% QoQ
2023 65
-22.6% YoY 103.1% QoQ
35
-68.5% YoY -46.2% QoQ
116
30.3% YoY 231.4% QoQ
0
-100.0% YoY -100.0% QoQ
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and BioCardia search interestLast update: November 04 2023 01:04:28.
Correlation coefficient between keyword and revenue is 0.8
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: November 04 2023 01:04:29.

The average 5 years interest of BioCardia was 4.2 per week.
The last year interest of BioCardia compared to the last 5 years has changed by 6.67%.
This is something to be checked.
This didn't exist 5 years ago.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for CardiAMP therapy to provide analysis

Correlation between past revenue and CardiAMP therapy search interest

There is not enough data for CardiAMP therapy to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for CardiAMP therapy to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for BioCardia heart failure to provide analysis

Correlation between past revenue and BioCardia heart failure search interest

There is not enough data for BioCardia heart failure to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for BioCardia heart failure to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 08 2024 16:20:01.

After 39 days of this quarter the interest is at 100.0. Based on that we can calculate that during remaining 52 days it will total up to 233.0.
Mesenchymal cell therapy expected interest is significantly higher compared to previous quarter (+482.5%) and same quarter last year (+50.3%).

YearQ1Q2Q3Q4
2019112
204
82.1% QoQ
84
-58.8% QoQ
129
53.6% QoQ
2020 153
36.6% YoY 18.6% QoQ
166
-18.6% YoY 8.5% QoQ
163
94.0% YoY -1.8% QoQ
139
7.8% YoY -14.7% QoQ
2021 111
-27.5% YoY -20.1% QoQ
188
13.3% YoY 69.4% QoQ
134
-17.8% YoY -28.7% QoQ
159
14.4% YoY 18.7% QoQ
2022 177
59.5% YoY 11.3% QoQ
107
-43.1% YoY -39.5% QoQ
117
-12.7% YoY 9.3% QoQ
151
-5.0% YoY 29.1% QoQ
2023 155
-12.4% YoY 2.6% QoQ
133
24.3% YoY -14.2% QoQ
87
-25.6% YoY -34.6% QoQ
40
-73.5% YoY -54.0% QoQ
2024 100
-35.5% YoY 150.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Mesenchymal cell therapy search interestLast update: February 08 2024 16:20:00.
Correlation coefficient between keyword and revenue is -0.76
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 08 2024 16:20:05.

The average 5 years interest of Mesenchymal cell therapy was 10.76 per week.
The last year interest of Mesenchymal cell therapy compared to the last 5 years has changed by -18.87%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -23.08%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Helix biotherapeutic delivery system to provide analysis

Correlation between past revenue and Helix biotherapeutic delivery system search interest

There is not enough data for Helix biotherapeutic delivery system to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Helix biotherapeutic delivery system to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Morph deflectable guides to provide analysis

Correlation between past revenue and Morph deflectable guides search interest

There is not enough data for Morph deflectable guides to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Morph deflectable guides to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for BioCardia careers to provide analysis

Correlation between past revenue and BioCardia careers search interest

There is not enough data for BioCardia careers to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for BioCardia careers to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for BioCardia reviews to provide analysis

Correlation between past revenue and BioCardia reviews search interest

There is not enough data for BioCardia reviews to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for BioCardia reviews to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for BioCardia California to provide analysis

Correlation between past revenue and BioCardia California search interest

There is not enough data for BioCardia California to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for BioCardia California to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: November 04 2023 01:06:59.

After 34 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 58 days it will total up to 0.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2018 - - - 193
2019 239
23.8% QoQ
174
-27.2% QoQ
166
-4.6% QoQ
158
-18.1% YoY -4.8% QoQ
2020 43
-82.0% YoY -72.8% QoQ
122
-29.9% YoY 183.7% QoQ
174
4.8% YoY 42.6% QoQ
264
67.1% YoY 51.7% QoQ
2021 144
234.9% YoY -45.5% QoQ
158
29.5% YoY 9.7% QoQ
197
13.2% YoY 24.7% QoQ
193
-26.9% YoY -2.0% QoQ
2022 151
4.9% YoY -21.8% QoQ
0
-100.0% YoY -100.0% QoQ
0
-100.0% YoY -100.0% QoQ
0
-100.0% YoY -100.0% QoQ
2023 0
-100.0% YoY -100.0% QoQ
0
-100.0% YoY -100.0% QoQ
0
-100.0% YoY -100.0% QoQ
0
-100.0% YoY -100.0% QoQ
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and BioCardia -stock -company search interestLast update: November 04 2023 01:06:59.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: November 04 2023 01:06:59.

The average 5 years interest of BioCardia -stock -company was 9.1 per week.
The last year interest of BioCardia -stock -company compared to the last 5 years has changed by -100.0%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -100.0%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for BCDA
Earnings date: 2024-03-27 After close
Company name: BioCardia Inc.
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-11T21:10:39Z

GlobeNewswire
BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026

2026-05-08T12:00:00Z

GlobeNewswire
BioCardia and FDA Align on Helix Transendocardial Delivery Catheter Clearance Pathways

2026-04-28T12:00:00Z

GlobeNewswire
BioCardia Announces Allowance of Japanese Patent on Proprietary Heart3D™ Fusion Imaging Software for Procedure Planning and Realtime Navigation During CardiAMP Cell Therapy Procedures

2026-04-20T12:00:00Z

GlobeNewswire
BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure

2026-04-02T14:11:34Z

GlobeNewswire
BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure

2026-03-24T20:05:00Z

GlobeNewswire
BioCardia Reports 2025 Business Highlights and Financial Results

2026-03-03T13:00:00Z

GlobeNewswire
BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT)

2026-02-10T14:15:00Z

GlobeNewswire
BioCardia Files Pre-Submission for FDA Approval of Helix™ Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart

2026-02-03T13:00:00Z

GlobeNewswire
BioCardia Announces Late Breaking Echocardiography Results from the CardiAMP HF Trial to be Presented at Technology and Heart Failure Therapeutics (THT)

2025-12-16T13:00:00Z

GlobeNewswire
BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA

2025-12-03T13:00:00Z

GlobeNewswire
BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno

2025-12-01T13:30:00Z

GlobeNewswire
BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress

2025-11-24T13:15:00Z

GlobeNewswire
BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality

2025-11-12T21:40:15Z

GlobeNewswire
BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results

2025-11-10T13:30:00Z

GlobeNewswire
BioCardia Announces Henry Ford Health Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial